Search Results for keywords:"Anesthetic and Analgesic Drug Products Advisory Committee"

The Food and Drug Administration (FDA) is hosting a joint public advisory committee meeting on February 5, 2025. This meeting involves the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee. The focus will be on discussing the outcomes of studies related to the risks associated with long-term use of extended-release/long-acting opioid analgesics. The FDA has opened a public comment docket, which will close on February 4, 2025, allowing individuals to submit their views electronically or by mail.

The Food and Drug Administration (FDA) announced a public advisory committee meeting of the Anesthetic and Analgesic Drug Products Advisory Committee. This meeting, scheduled for January 10, 2025, is open to the public and can be attended either in person at the FDA campus in Silver Spring, MD, or online. The meeting will discuss the Biologics License Application for condoliase injection, aimed at treating radicular leg pain associated with lumbar disc herniation. The FDA is also accepting public comments on this topic until January 9, 2025, and encourages individuals to submit their views electronically or via written submissions.